Geron | GERN

Stock Price
1.40
Daily Change
0.02 1.45%
Monthly
0.72%
Yearly
-67.06%
Q3 Forecast
1.39

Peers Price Chg Day Year Date
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Geron 1.40 0.02 1.45% -67.06% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Cassava Sciences 2.16 0.01 0.47% -91.97% Sep/05
Bio Techne 54.41 1.49 2.82% -24.00% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Geron traded at $1.40 this Friday September 5th, increasing $0.02 or 1.45 percent since the previous trading session. Looking back, over the last four weeks, Geron gained 0.72 percent. Over the last 12 months, its price fell by 67.06 percent. Looking ahead, we forecast Geron to be priced at 1.39 by the end of this quarter and at 1.35 in one year, according to Trading Economics global macro models projections and analysts expectations.

Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).